Status:
COMPLETED
Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice
Lead Sponsor:
Sun Pharmaceutical Industries, Inc.
Conditions:
Pediculosis
Eligibility:
All Genders
6-24 years
Phase:
PHASE2
PHASE3
Brief Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation ...
Eligibility Criteria
Inclusion
- Confirmed active head lice infestation
Exclusion
- Allergy to pediculicides or hair care products
- Scalp conditions other than head lice
- Previous head lice treatment within the past 4 weeks
- Current antibiotic treatment
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00752973
Start Date
September 1 2008
End Date
January 1 2012
Last Update
August 7 2014
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigator Site
Bentonville, Arkansas, United States
2
Investigator Site
Jonesboro, Arkansas, United States